PressFebruary 17, 2026 Compass hits primary endpoint in second Phase 3 psilocybin trial, giving it two positive pivotal studies
PressFebruary 9, 2026 Clearmind reports additional positive safety data for CMND-100 in alcohol use disorder
PressFebruary 4, 2026 Trump administration officials strip Compass psilocybin from FDA fast-track voucher list
PressJanuary 26, 2026 Optimi Health completes first 2026 production run of MDMA and psilocybin capsules
PressJanuary 12, 2026 MindMed unveils full rebrand as Definium Therapeutics, spotlighting late-stage LSD pipeline
Psychedelic NewsJanuary 4, 2026 Psychedelic Sector Week in Review: December 29, 2025 – January 4, 2026
